Scott Coleman
Corporate Officer/Principal bij XILIO THERAPEUTICS, INC.
Actieve functies van Scott Coleman
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| XILIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01-06-2022 | - |
Loopbaan van Scott Coleman
Eerdere bekende functies van Scott Coleman
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - | - |
Opleiding van Scott Coleman
| North Carolina State University | Doctorate Degree |
| Northeastern University | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
- Beurs
- Insiders
- Scott Coleman
- Ervaring
